# Immune Intervention With Rituximab to Preserve Beta Cell Function in Early Onset Type 1 Diabetes

> **NCT01280682** · PHASE4 · COMPLETED · sponsor: **Yang Tao** · enrollment: 120 (actual)

## Conditions studied

- Type 1 Diabetes

## Interventions

- **DRUG:** rituximab

## Key facts

- **NCT ID:** NCT01280682
- **Lead sponsor:** Yang Tao
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07
- **Primary completion:** 2016-12
- **Final completion:** 2018-12
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2023-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01280682

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01280682, "Immune Intervention With Rituximab to Preserve Beta Cell Function in Early Onset Type 1 Diabetes". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT01280682. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*